Use of artesunate in non-malarial indications.
Autor: | Raffetin A; Service de maladies infectieuses et tropicales et de médecine interne, CHI Lucie-et-Raymond-Aubrac, 94190 Villeneuve Saint-Georges, France., Bruneel F; Service de réanimation médicale, centre hospitalier de Versailles, hôpital André-Mignot, 78150 Le Chesnay, France., Roussel C; Inserm, unité biologie intégrée du globule rouge, laboratoire d'excellence GR-Ex, Sorbonne universités, université Paris Descartes, INTS, 75015 Paris, France., Thellier M; Centre national de référence pour le paludisme, 75013 Paris, France; Service de parasitologie-mycologie, groupe hospitalier Pitié-Salpêtrière, AP-HP, 75013 Paris, France., Buffet P; Inserm, unité biologie intégrée du globule rouge, laboratoire d'excellence GR-Ex, Sorbonne universités, université Paris Descartes, INTS, 75015 Paris, France; Centre national de référence pour le paludisme, 75013 Paris, France., Caumes E; Service des maladies infectieuses et tropicales, groupe hospitalier Pitié-Salpêtrière, AP-HP, 75013 Paris, France; Inserm, institut Pierre-Louis d'épidémiologie et de santé publique (UMRS 1136), Sorbonne universités, UPMC université Paris 06, 75013 Paris, France., Jauréguiberry S; Centre national de référence pour le paludisme, 75013 Paris, France; Service des maladies infectieuses et tropicales, groupe hospitalier Pitié-Salpêtrière, AP-HP, 75013 Paris, France; Inserm, institut Pierre-Louis d'épidémiologie et de santé publique (UMRS 1136), Sorbonne universités, UPMC université Paris 06, 75013 Paris, France. Electronic address: stephane.jaureguiberry@aphp.fr. |
---|---|
Jazyk: | angličtina |
Zdroj: | Medecine et maladies infectieuses [Med Mal Infect] 2018 Jun; Vol. 48 (4), pp. 238-249. Date of Electronic Publication: 2018 Feb 13. |
DOI: | 10.1016/j.medmal.2018.01.004 |
Abstrakt: | Introduction: Artesunate and other artemisinin derivatives are used in various infectious and non-infectious diseases. We aimed to analyze available data on artesunate and artemisinin derivatives activity in humans and their potential clinical benefits in non-malarial indications. Material and Methods: Literature review performed on PubMed and the Cochrane Library databases using the PRISMA method. We analyzed studies published in English from January 2008 to August 2017 using the same indicators of drug efficacy. Results: We included 19 studies performed in humans (1 meta-analysis, 1 literature review, 4 randomized controlled trials, 3 prospective controlled trials, 3 prospective uncontrolled trials, 2 exploratory phase 1 or 2 trials, 1 case series, and 4 case reports). Artesunate and artemisinin derivatives demonstrated efficacy in the treatment of schistosomiasis in combination with praziquantel (P=0.003). Artesunate monotherapy was less effective than praziquantel alone (P<0.001) probably because its activity only affects the early stages of Schistosoma parasites. Artesunate monotherapy could be interesting as a chemoprophylactic drug against schistosomiasis (P<0.001). Findings seem promising but are still controversial in the treatment of multidrug-resistant CMV infections. Studies do not conclude on artesunate and artemisinin derivatives efficacy in the treatment of cervix, breast, colorectal, and lung cancers. Conclusion: Artesunate and artemisinin derivatives in combination with praziquantel were effective against schistosomiasis, and could be used as a chemoprophylactic drug alone. They could be interesting as anti-CMV and anti-tumor treatment. Additional trials in humans are required to assess the efficacy of artesunate and artemisinin derivatives in diseases other than malaria. (Copyright © 2018 Elsevier Masson SAS. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |